Using Magnetic Field Tracking to Confirm Nasogastric Tube Placement at Point of Care

April 23, 2023 updated by: Tan Tock Seng Hospital

Using Magnetic Field Tracking to Confirm Nasogastric Tube Placement at Point of Care, A Feasibility Study

This is a trial on the feasibility of magnetic tracking for the confirmation of nasogastric tube location in human patients.

Study Overview

Detailed Description

In order to address the clinical need for the localization of nasogastric tube (NGT) at point-of-care, Nanyang Technological University, Tan Tock Seng Hospital and Woodlands Health Campus co-developed the prototype of a medical device that consists of a guidewire attached to a gold-plated Neodymium magnet to be used with a T-shaped body-worn sensors connected to a laptop. The magnetic-tipped guidewire is compatible with 14Fr or larger Ryles tubes. The sensors are passive and are designed to fit on the patient's sternum beginning at the level of the second intercostal space or xiphisternum. These sensors can track the changes in magnetic flux density real-time as the magnetic-tipped guidewire is inserted into the lumen of an NGT. The tracking may be done during NGT insertion or before feeding if confirmation of its location is required. The changes in magnetic flux density will be used to determine the location of the magnet in relation to the sensors. The result of these computations will be displayed on the computer screen as a trajectory of the magnet's movement inside the NGT. At full insertion of the guidewire, the trajectory should correspond to the actual location of the NGT in the patient.

This device is currently not in use but the investigators have notified the Health Science Authority of Singapore for its use as a Clinical Research Material.

The investigators aim to recruit 12 adult patients from both gender (6 each) who would already have had NGT placement and confirmation of its position by CXR within 48 hours of NGT insertion. These patients may have a variety of body habitus and will be screened according to a detailed list of exclusion criteria that rules out a recent medical history of oesophageal or gastric surgery, cardiac stent, pacemaker, implantable defibrillator or ferromagnetic implants in the neck, thorax, abdomen, pelvis or spine.

The investigators plan to test the following hypotheses and safety parameters.

  1. Concordance of our tracking with the trajectory of the NGT seen on chest X-ray
  2. The vertical and horizontal range of tracking
  3. The ability to detect a leftward deviation from the midline inferior to the xiphisternum
  4. Test-retest reliability
  5. Adverse events related to the magnetic-tipped guidewire or the sensors

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- Patients from the general ward or the Otorhinolaryngology clinic of Tan Tock Seng Hospital who had an NGT inserted within the last 10 days and chest X-ray confirming its correct placement

  • The NGT inserted is a Ryles tube size Fr 14 or 16
  • COVID negative or not deemed to be infective as judged by the prevailing policies at the time of recruitment
  • Age > or = 21 years
  • BMI < 35
  • Height < 1.9m
  • Mentally competent for informed consent

Exclusion Criteria:

  • • Radiological:

    • On chest X-ray, the length of the NGT distal to the gastroesophageal junction is less than 12cm, or the side-holes of the NGT can be visualized in the esophagus.
    • The NGT is kinked within 10cm of its tip
    • The chest X-ray is rotated such that the thorax is not oriented in the frontal plane
    • The NGT cannot be visualized in the mediastinum
    • The second intercostal space cannot be visualized on chest X-ray

      • Medically unstable:

    • Heart rate >=100 or <60
    • Systolic blood pressure >=160 or <100
    • SpO2 <92% in patients with chronic lung disease and <95% in patients without chronic lung disease
    • Temperature >= 38 degrees Celsius

      • Chest wall deformity:

    • Patients with pectus carinatum or excavatum, defined by physical examination

      • Patients with the following implants

    • Pacemaker
    • Automatic cardioverter defibrillator
    • Ferromagnetic coronary stents or heart valves
    • Ferromagnetic implants of the cranium, face, spine, sternum or ribs
    • Ferromagnetic surgical clips or implants in the head, neck, thorax, abdomen or pelvis

      • Following conditions within the last 30 days

    • Upper gastrointestinal bleeding
    • Oesophageal or gastric surgery
    • Stroke
    • Myocardial infarction
    • Aortic dissection
    • Ruptured aortic aneurysm

      • Allergy to neodymium, gold, epoxy or nitinol
      • Not able to understand English, Chinese, Malay or Tamil
      • Women whose last menstrual period commenced more than 4 weeks before recruitment unless they have a negative urinary or serum pregnancy test during their current admission.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Magnetic tracking
This is the only arm of the study. All 12 participants will undergo the insertion of the magnetic-tipped guidewire into their nasogastric tube after its correct placement is confirmed by chest X-ray.
In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Probability of visualising a leftward deviation of the magnetic tipped guide-wire inferior to the xiphisternum
Time Frame: 6 months
The investigators will measure the rate of visualisation of a left-ward deviation of the magnet below the plane of xiphisternum in participants whose nasogastric tube deviates in such a way on chest X-ray.
6 months
Difference in the distance between the magnet and the datum with that between the nasogastric tube on chest X-ray and the datum
Time Frame: 6 months
The investigators will compare difference in distance (measured in millimetres) between the path of the nasogastric tube seen on magnetic tracking with that seen on chest X-ray by comparing them against a vertical midline (datum) centred over the midpoint of the sternum.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
test-retest variability
Time Frame: 6 months
The investigators will compare the distance between the magnet and the datum at the insertion of the guide-wire against that obtained at withdrawal in order to determine the variation in the accuracy of the tracking with repeated testing.
6 months
Adverse events related to the device
Time Frame: 6 months
The investigators will record the incidence of magnet dislodgement, breakage of the guidewire, pain during insertion and withdrawal of the device, dermatitis over the chest wall in reaction to the sensors and any other unexpected adverse events caused by the device.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 4, 2022

Primary Completion (Actual)

December 7, 2022

Study Completion (Actual)

December 7, 2022

Study Registration Dates

First Submitted

December 5, 2021

First Submitted That Met QC Criteria

January 10, 2022

First Posted (Actual)

January 24, 2022

Study Record Updates

Last Update Posted (Actual)

April 25, 2023

Last Update Submitted That Met QC Criteria

April 23, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Anonymized IPD may be shared with other researchers upon reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastrointestinal Diseases

3
Subscribe